Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Ceva Animal Health and Touchlight sign an agreement to use Touchlight’s dbDNA technology in animal health >
Ceva and Touchlight entered into an agreement and a long-term collaboration for the development and manufacture of new dbDNA vaccines and therapeutics across a broad range of animal health indications.
Ceva Names New SVP for North America >
Brad McCollum will lead Ceva’s business in the United States and Canada.
Seeking Projects Advancing Human-Animal Bond >
Event seeks innovative solutions for the well-being and care of companion animals and their pet parents.
PANOQUELL®-CA1 (fuzapladib sodium for injection) is now available in the U.S. >
The first and only drug conditionally approved by the FDA for management of the symptoms associated with acute onset of canine pancreatitis
WVA Global Veterinary Awards launched >
New awards recognize work in One Health, Animal Welfare, Medicine Stewardship and Veterinary Education
Ceva Launches Wildlife Research Fund >
Ceva Wildlife Research Fund, the first endowment fund dedicated to research to protect wildlife.
CEVA EXPANDS ORAL RABIES VACCINE PORTFOLIO WITH THE ACQUISITION OF CANADIAN FIRM ARTEMIS TECHNOLOGIES, INC. >
Libourne, May 16, 2022 – Ceva Santé Animale (Ceva) has acquired the Canadian oral rabies vaccine manufacturer Artemis Technologies, Inc. Artemis, located in Guelph, ON, Canada, produces ONRAB®, a rabies glycoprotein recombinant oral vaccine licensed for use in striped skunks (Mephitis mephitis) in Canada. The product also had positive field trial use in the USA in wild raccoons and skunks. "Ceva’s...
Ceva Helps to Expand COVID-19 Testing >
MAWD Pathology increases same-day COVID-19 testing using equipment on loan from Ceva
Ceva Returns Strong Double-Digit Growth in 2019; Plans to Double sales by 2020. >
Consolidated sales of the Ceva Group reached more than €1.2 billion in 2019.
Program Receives Quality Recognition >
Ceva’s U.S. C.H.I.C.K Program receives independently audited quality recognition from Bureau Veritas